Search

Displaying results 2291 - 2300 of 10000 in total
  1. Drug

    Phloxine B

    go.drugbank.com/drugs/DB13911
    ApprovedWithdrawn

    Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.

  3. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    episodes in patients with hemophilia A. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.

  4. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency

  5. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost. … In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone.

  6. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUS
  7. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

  8. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    Piperazine was first introduced as an anthelmintic in 1953. … First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953.

  9. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

  10. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.